Nathalie A. Johnson

University of Lahore — Pakistan

Medicine · Health Sciences

48h-index15.5kcitations278works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(204), Chronic Lymphocytic Leukemia Research(79), CAR-T cell therapy research(58), Cancer Immunotherapy and Biomarkers(33), Cancer Genomics and Diagnostics(31)

Publications278 total

The CCL17–CCR4 Axis Is Critical for Mutant STAT6-Mediated Microenvironmental Remodeling and Therapeutic Resistance in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Cancer Immunology Research·2025Open Access
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma
Future Oncology·2025Open Access
<b>PREVALENCE OF BURNOUT SYNDROME (BOS) AND ITS ASSOCIATION WITH PROFESSIONAL QUALITY OF LIFE AMONG CLINICAL PHYSICAL THERAPISTS.</b>
Journal of medical & health sciences review.·2025Open Access
Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti–PD-1–refractory Hodgkin lymphoma
Blood Advances·2025Open Access
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy
Leukemia & lymphoma/Leukemia and lymphoma·2025Open Access
SUVR (SUVmax Lymphoma/SUVmax Liver) vs. Deauville score for predicting PFS in Hodgkin Lymphoma
Clinical and Translational Imaging·2025· 1 cited
421 | ctDNA DYNAMICS OF REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Hematological Oncology·2025Open Access
134 | EFFICACY AND SAFETY OF FIRST‐LINE IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO WERE OLDER OR HAD TP53 MUTATIONS IN THE SYMPATICO STUDY
Hematological Oncology·2025· 1 citedOpen Access
Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysisImpact of B-cell malignancy therapy on COVID-19 outcomes
UNC Libraries·2025Open Access
A low lymphocyte‐to‐monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis
British Journal of Haematology·2025· 1 citedOpen Access
The CCL17-CCR4 axis is critical for mutant STAT6-mediated microenvironmental remodelling and therapeutic resistance in Relapsed/Refractory Diffuse Large B Cell Lymphoma
2024Open Access
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ
JAMA Oncology·2024· 12 citedOpen Access
FL molecular subgroups come of age
Blood·2024Open Access
PCR241 Targeted Literature Review of in-Trial/Exit Interviews in Clinical Trials Focusing on Multiple Myeloma and Related Conditions
Value in Health·2024Open Access
SUVR (SUVmax Lymphoma/SUVmax Liver) Vs Deauville Score for Predicting Relapse in Hodgkin Lymphoma
Blood·2024Open Access
Analysis by TeloView® Technology Predicts the Response of Hodgkin’s Lymphoma to First-Line ABVD Therapy
Cancers·2024· 1 citedOpen Access
Identification of genetic subtypes in follicular lymphoma
Blood Cancer Journal·2024· 12 citedOpen Access
Single gene mutations and prognosis in limited‐stage follicular lymphoma treated with radiation therapy
British Journal of Haematology·2024· 3 citedOpen Access
A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis.
Journal of Clinical Oncology·2024· 1 cited
A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis.
Journal of Clinical Oncology·2024· 2 cited
page 1 of 14Next →

Frequent Co-authors

Randy D. Gascoyne(33), Joseph M. Connors(25), Ryan D. Morin(15), Marco A. Marra(12), Christian Steidl(12), David W. Scott(10), Susana Ben‐Neriah(10), Lisa M. Rimsza(9), Andrew J. Mungall(8), Douglas E. Horsman(8), Laurie H. Sehn(8), Merrill Boyle(7), Sohrab P. Shah(7), Andreas Rosenwald(7), Elı́as Campo(7), Louis M. Staudt(7), Pedro Farinha(7), Bruce W. Woolcock(6), German Ott(6), Wing C. Chan(6)